About
Hubert Löwenheim is Medical Director of the ENT University Clinic in Tübingen and Principal Investigator of “Regenerative Biology Group”. He has extensive experience in the field of regenerative hearing loss therapies both scientifically and clinically. He was the first describing the involvement of cell cycle regulators esp. p27Kip1 in the proliferation and differentiation of hair cells and supporting cells in the cochlea. In 1998, based on these discoveries he co-founded the company Otogene AG in Tübingen and its subsidiary Otogene Inc. in Seattle with the aim to identify an inhibitor of p27Kip1 as regenerative drug. Hubert Löwenheim received his MD from Goethe University, Frankfurt am Main and trained in Otorhinolaryngology at the University of Tübingen. His doctoral degree from Goethe University is in auditory physiology, his Habilitation degree from Tübingen University is in auditory regenerative biology. His clinical focus is in Otology & Neurootology. He has published over 50 sc
Position in the VCSift Database
- • 2,490 investors hold the Founder role in VCSift. Hubert Löwenheim is one of them.
- • 5 investors are based in Tübingen, Baden-Wurttemberg, Germany.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Tübingen, Germany
Contact Information
Find more investors like Hubert
Search Investors